knowledge -WSS

knowledge

author：leisure time 2025-09-29 21:26:50 - browse：46

Illustration oh researchers look up at a blister pill pac. Part of the blister pack is filled with pills, while the center shows a sketch of a brain. -- biotech coverage from STAT — Mike Reddy for STAT

One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry.

It was the early 2000s, and as America warmed to the sounds of Sisqó and Shakira, the world’s largest pharmaceutical firms were running out of ideas to treat mental illness. Their blockbuster treatments for depression and schizophrenia had reshaped society and made billions of dollars in the process, but the old cash cows were soon to go generic. Efforts to one-up the last generation of drugs mostly resulted in incremental changes to aging medicines. And when insurance companies balked at paying brand-name prices for extended-release generics, the money dried up and the industry moved out.

“The mindset of Big Pharma in those days was one pill for millions and millions of people,” said John LaMattina, who led Pfizer’s research division from 1999 to 2007. “Everyone was looking for the next Lipitor, and when that fizzled out, there was an exodus out of psychotherapeutic areas.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： FDA clears AI tool for detecting skin cancer

focus

WSS

EU regulator recommends expanding Mounjaro approval to obesity

DeSantis can now import cheaper drugs. But will Biden get credit?

Medicare Advantage today, explained in one chart

Designating disabled people as health disparity population is crucial

Risky weight loss products often used by teens globally, per study

Research misconduct: Proposed new rules face resistance

explore

knowledge

focus

Apple is now the first public company to be valued at $3 trillion

Humana cuts profit projections as Medicare Advantage costs soar

Wildfire smoke exposes gaps in outdoor worker protections

As JPM 2024 winds down, some health tech firms project optimism

Alkermes shareholders re

Readout LOUD podcast: live from JPM 2024

The high cost of giving birth even with insurance

EU regulator recommends expanding Mounjaro approval to obesity

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

GSK to buy asthma

entertainment

Readout Newsletter: Merck, J&J, and long Covid

Readout LOUD podcast: live from JPM 2024

New England Journal of Medicine addresses racist history, slavery

Eli Lilly, Pfizer, and others want in on the online prescription market

Why doctors need education on FDA device approval process

AI generated plenty of interest at JPM but not a lot of trust

focus

hotspot

focus

explore